Recent Updates
Recently added Catalysts

Moxifloxacin, 0.5%

Phase 3

Bacterial Conjunctivitis | Small molecule | Infectious Disease |Alcon Inc.|Last Updated: May 12, 2015

Target and mechanism

ModalitySmall molecule

Also known as Moxifloxacin ophthalmic solution, 0.5%

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment985

FDA Designations

No designations recorded

Clinical trial landscape

Moxifloxacin, 0.5% · 1 trial · 1 indication

Phase 3 1
NCT01573910An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese PatientsBacterial Conjunctivitis
COMPLETED985 Analytics
PHASE3COMPLETED
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
Bacterial ConjunctivitisUnlock trial analytics

Study Endpoints

Primary Endpoints

Clinical Cure Rate
Day 9

Ocular signs of bacterial conjunctivitis (bulbar conjunctival injection and conjunctival discharge/exudates) were rated by the investigator on a 4-point scale, with 0=normal/absent; 1=mild; 2=moderate, and 3=severe. Clinical cure rate is presented as the percentage of participants for which the sum of the numerical scores for the 2 cardinal ocular signs of bacterial conjunctivitis was 0 at Day 9 TOC/Exit Visit.

Microbiological Success Rate
Day 9

Microbiological specimen(s) from the affected eye(s) were collected according to a protocol-defined process. Microbiological success rate is presented as the percentage of participants for which the pre-therapy pathogens at Visit 1 (Day 1) were eradicated at Day 9 TOC/Exit Visit.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
MoxifloxacinEXPERIMENTALMoxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
OfloxacinACTIVE_COMPARATOROfloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9

Interventions

NameTypeDescription
Moxifloxacin ophthalmic solution, 0.5%DRUG -
Ofloxacin ophthalmic solution, 0.3%DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range1 Year to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Chinese. * Diagnosis of bacterial conjunctivitis based on clinical observation. * Understand and sign the approved informed consent. Legally authorized representative can provide informed consent for patients less than 18 years old and/or incapable of understanding the informe...

Countries:China
Unlock Eligibility Criteria